Navigation Links
Ruboxistaurin As A Novel Treatment For Diabetic Nephropathy

Recent research, which appears in the current issue of Diabetes Care, establishes Ruboxistaurin as a promising novel treatment that may improve upon established therapies for diabetic nephropathy//.

Nephropathy is known to develop in 40% of people with type 2 diabetes and is the leading cause of end-stage renal disease in the U.S. and the developed world.

Many persons with diabetes have progressive nephropathy even with the established therapies. Therefore, treatments targeting novel pathogenic mechanisms may be beneficial.

Studies have shown an important role for protein kinase C (PKC)-? in the pathogenesis of diabetic nephropathy. Ruboxistaurin selectively inhibits protein kinase C-? and ameliorates kidney disease in animal models of diabetes.

The study was performed to evaluate the effects of 32mg/day ruboxistaurin for 1 year in persons with type 2 diabetes and persistent albuminuria persistent albuminuria (albumin-to-creatinine ratio [ACR] 200-2,000 mg/g), despite therapy with renin-angiotensin system inhibitors. The primary end point was a change in the ACR. Estimated glomerular filtration rate (eGFR) was also calculated.

It was found that after one year, urinary ACR decreased significantly in participants treated with ruboxistaurin and nonsignificantly in the placebo group. The ACR-lowering effect of ruboxistaurin appeared by 1 month. eGFR did not decline significantly in the ruboxistaurin group, whereas the placebo group lost significant eGFR over 1 year.

Between-group differences for changes in ACR and eGFR were not statistically significant, but this pilot study was underpowered to determine such differences.

The study authors conclude that ruboxistaurin had favorable effects on albuminuria and renal function in persons with type 2 diabetes and nephropathy. The albuminuria-lowering effect occurred early and was sustained long term. Those treated with ruboxista urin did not experience a significant decline in renal function. Ruboxistaurin may thus add benefit to established therapies for diabetic nephropathy. The authors suggest that large-scale trials should be performed to confirm its effectiveness and safety.
'"/>




Related medicine news :

1. Ruboxistaurin (RBX) may prevent vision loss in diabetic patients
2. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
3. Novel biopsy technique for prostate cancer
4. Novel computer model for breast cancer
5. Novel research on liver cancer
6. Novel way to fight cancer
7. Novel test for bowel cancer
8. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
9. Novel Therapy for Chronic Problem
10. Blood Sugar Kept In Control By Novel Protein
11. Novel antibiotic dressing developed for improved wound healing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... AR (PRWEB) , ... October 13, 2017 , ... ... with locations throughout Arkansas that offers insurance and financial preparation services, is providing ... the Rock City Rescue organization. , Rock City Rescue is a locally recognized ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology: